glp 1 oral novo nordisk launches its Wegovy Pill weight-loss drug to the US market, GoodRx discounts it BREAKING: The FDA has approved
Description
This blog is part of an ongoing series on A Brave New World: Therapeutic Area Deep Dives
Key Findings: - Increased risk of going over recommended weight gain limits - Higher chances of preterm birth (from 13% to 17%) - Rising cases of gestational diabetes (15% to 20%) - Nearly half faced high blood pressure issues While baby sizes and C-section rates remained similar, the impact on maternal health is significant
The Tirzepatide Revolution: Is Dual Agonism the End of Single-Pathway Therapy
No stimulants
Explore GLP-1 insights, including trends in online prescriptions, increased fruit and vegetable consumption, and shopping intent among users.
Main outcome measures Thyroid cancer identified from nationwide cancer registers
